Aqilion resolves on issue in kind
AQILION AB (publ) is announcing today that the company’s Board of Directors has resolved on an issue in kind in accordance with the acquisition of the Regulus program from LEO Pharma at the end of 2021. The Board was authorized to carry out such a resolution by the Annual General Meeting on June 18, 2021. Under the agreement with LEO Pharma, Aqilion is to pay a final instalment for the acquisition of the Regulus program when the Phase I clinical trial is approved by issuing 221,527 Aqilion shares to LEO Pharma. The Board has therefore resolved on the issue today according to the